news
GSK receives marketing authorisation from the European Commission for Tafinlar™ (dabrafenib)
2 September 2013 | By GlaxoSmithKline
GSK announced that the European Commission has granted marketing authorisation for Tafinlar™ (dabrafenib)...
List view / Grid view
GlaxoSmithKline (GSK)
news
New carbon footprint tool launched to calculate the carbon footprint of pharmaceutical products
28 August 2013 | By Carbon Trust
ABPI collaborates with the Carbon Trust to help pharmaceutical companies quickly estimate the carbon footprint of tablet medicines distributed in blister packs...
news
GSK announces phase III study of vercirnon in patients with moderate-to-severe Crohn’s disease did not meet its primary endpoint
23 August 2013 | By GlaxoSmithKline
The first of four Phase III studies, the SHIELD-1 study, investigating vercirnon in adult patients with moderately-to-severely active Crohn’s disease did not achieve the primary endpoint...
news
GSK receives EMA approval for new Tyverb® (lapatinib) indication in combination with trastuzumab
19 August 2013 | By Packer Forbes Communications
The EMA has granted an update to the marketing authorisation for Tyverb® (lapatinib) to be used in combination with Herceptin® (trastuzumab)...
news
GSK receives marketing authorisation from the European Commission for additional indication: Tyverb™ (lapatinib) in combination with trastuzumab for patients with HER2-positive, HR-negative metastatic breast cancer
14 August 2013 | By GlaxoSmithKline
“Today’s announcement is important for women with this specific type of metastatic breast cancer..."
news
GSK launches $50 million venture capital fund to invest in pioneering bioelectronic medicines and technologies
8 August 2013 | By GlaxoSmithKline
GlaxoSmithKline announced the launch of Action Potential Venture Capital (APVC) Limited...
news
GSK announces EU submission seeking additional indication for Votrient® as maintenance therapy for advanced ovarian cancer
6 August 2013 | By GlaxoSmithKline
“This EU filing, the third for pazopanib in less than five years, confirms GSK’s commitment to deliver our oncology pipeline..."
news
albiglutide US PDUFA date extended by three months
2 August 2013 | By GlaxoSmithKline
GlaxoSmithKline announced that the US Prescription Drug User Fee Act (PDUFA) goal date for albiglutide has been extended by three months...
news
GSK adds to its commitment to GAVI Alliance to help protect millions more children against infectious diseases
29 July 2013 | By GlaxoSmithKline
New extension of Synflorix vaccine supply agreement will help protect an additional 80 million children...
news
GSK receives positive CHMP opinion for REVOLADETM in thrombocytopenia associated with chronic hepatitis C infection
26 July 2013 | By GlaxoSmithKline
“A sustained virologic response is the goal for treatment of hepatitis C infection..."
news
GSK announces US submission for dabrafenib/trametinib combination in metastatic melanoma
9 July 2013 | By GlaxoSmithKline
GSK announced submission of NDAs to the US FDA for use of dabrafenib...
news
Student becomes first recipient of unique Strathclyde degree with GSK
4 July 2013 | By GlaxoSmithKline
A student has become the first to graduate from a landmark research programme run by the University of Strathclyde...
news
GSK receives positive CHMP opinions for Tafinlar® (dabrafenib) and Tyverb® (lapatinib)
28 June 2013 | By GlaxoSmithKline
The EMA's CHMP is recommending marketing authorisation for two cancer drugs...
news
GSK’s drisapersen to receive FDA breakthrough therapy designation for potential treatment of patients with DMD
27 June 2013 | By GlaxoSmithKline
GlaxoSmithKline has received a verbal notification...
news
GSK and Save the Children launch $1 million award to discover new healthcare innovations for reducing child deaths
27 June 2013 | By GSK
GSK and Save the Children today launched a $1 million Healthcare Innovation Award...
